An Evening With the Experts: Clinical Decision-Making for Patients With HR+ HER2- Early Breast Cancer

Hear from the experts on how the latest clinical data inform the use of biomarkers to assess risk and selection of CDK4/6 inhibitor&ndash based therapy for patients with HR+/HER2- early breast cancer in these downloadable slides and on-demand webcast from a live CCO webinar.

Share

Program Content

No activities added yet

Activities

HR+/HER2- EBC Tx Benefit
Prognostic and Predictive Measures of Therapeutic Benefit in Early Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 15, 2021

Expires: June 14, 2022

Adj Tx for HR+/HER2- EBC
Adjuvant Therapy for Patients With HR+/HER2- EBC at High Risk of Recurrence
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2021

HR+/HER2- EBC Neoadj Tx
Neoadjuvant Therapy Considerations With CDK4/6 Inhibitors in HR+/HER2- EBC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 15, 2021

Expires: June 14, 2022

<i>EP</i>: HR+/HER2- EBC
ExpressPoints:
Clinical Decision-Making for Patients With HR+ HER2- Early Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 18, 2021

Expires: June 17, 2022

Faculty

cover img faculity

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

cover img faculity

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Lilly